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Fibronectin Peptides that Bind PDGF-BB Enhance
Survival of Cells and Tissue under Stress
Fubao Lin1, Jia Zhu2, Marcia G. Tonnesen3,4, Breena R. Taira5, Steve A. McClain6, Adam J. Singer6
and Richard A.F. Clark1,3
Stressors after injury from a multitude of factors can lead to cell death. We have identified four fibronectin (FN)
peptides: two from the first FN type III repeat (FNIII1), one from the 13th FN type III repeat (FNIII13), and one from
FN variable region (IIICS), which when tethered to a surface acted as platelet-derived growth factor-BB (PDGF-BB)
enhancers to promote cell survival. One of the FNIII1 peptides and its smallest (14-mer) bioactive form (P12) were
also active in solution. Specifically, P12 bound PDGF-BB (KD¼ 200nM), enhanced adult human dermal fibroblast
(AHDF) survival under serum starvation, oxidative or endoplasmic reticulum stressors, and limited burn-injury
progression in a rat hot comb model. Furthermore, P12 inhibited endoplasmic reticulum stress–induced c-Jun
N-terminal kinase (JNK) activation. Although many growth factors have been found to bind FN directly or
indirectly, here we identify peptide sequences of growth factor–binding sites in FN. The finding of these peptides
further delineated how the extracellular matrix protein FN can support cell survival. As the peptide P12 is active in
either soluble form or tethered to a substrate, it will have multifactorial uses as a bioactive peptide by itself or in
tissue engineering.
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INTRODUCTION
Tissue injury after stroke, heart attack, burns, or other trauma
is a dynamic process that extends in size and severity over
several days, leading to excess mortality and morbidity (Brait
et al., 2010; Shupp et al., 2010; Piper and Garcia-Dorado,
2012). After injury, the central necrotic tissue is surrounded by
ischemic, less severely affected tissue that potentially remains
salvageable. However, as the ischemic tissue is exposed to
various stresses such as nutrition depletion, reactive oxygen
species (ROS), cytokines, and hypoxia, tissue cells in this
region often die, by either apoptosis or necroptosis (Galluzzi
and Kroemer, 2008; Lanier et al., 2011; Hirth et al., 2013),
unless effective postinjury therapy is given (Yuan, 2009).
Hence, preventing cell death in potentially salvageable
tissue of an acutely damaged organ is a major goal for
therapies of these injuries.
Fibronectin (FN) (Figure 1a), an extracellular protein found
in blood and connective tissue, has a crucial role in cell
growth, survival, migration, angiogenesis, and wound healing
(Yamada and Clark, 1996). In the absence of tissue cell–
derived FN, plasma FN can support neuronal survival and
reduce brain injury following transient focal cerebral ischemia
(Sakai et al., 2001). Although FN probably supports cell
survival in many ways, one mechanism is the interaction of
RGD peptide in the 10th FN type III repeat (FNIII10) with
integrin receptors. For example, the FN integrin receptor a5b1
supports Chinese hamster ovary cell survival and upregulates
Bcl-2 expression (Zhang et al., 1995). In addition, FN-ligated
a5b1 and avb3 integrins promote brain capillary endothelial
cell survival and proliferation via mitogen-activated protein
kinase signaling (Wang and Milner, 2006). FN-dependent
survival signaling transits through phosphatidylinositide 3
kinase and NF-kB pathways in human bronchial epithelial
cells (Han and Roman, 2006).
Platelet-derived growth factors (PDGFs) are major mitogens
and survival factors for most mesenchymal cell types including
fibroblasts (Romashkova and Makarov, 1999). PDGF occurs as
five isoforms, classic PDGF-AA, AB, and BB isoforms, and the
more recently described PDGF-CC and PDGF-DD isoforms
(Fredriksson et al., 2004). The most potent PDGF isoforms,
-AB and -BB, are secreted either by platelets (PDGF-AB),
macrophages (PDGF-BB), or epidermal cells (PDGF-BB) in
response to injury. PDGFB knockout in mice is embryonic
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lethal, whereas knockouts of other isoforms are not (Betsholtz,
2004).
Survival signals from FN and growth factors converge at
the level of the focal contact (Plopper et al., 1995) and are
costimulatory (Miyamoto et al., 1996) for progression through
the cell cycle (Assoian and Schwartz, 2001). For example,
FN can bind vascular endothelial growth factor and enhance
its bioactivity (Wijelath et al., 2006). It was more recently
demonstrated that FNIII12–14 bound a large number of growth
factors (Martino and Hubbell, 2010) including PDGF-BB,
which we confirmed (Lin et al., 2011). Furthermore, we
demonstrated that FN contains three growth factor–binding
(FN-GFB) domains, i.e., FNIII1, FNIII13, and IIICS, respectively,
which worked cooperatively with PDGF-BB to sustain optimal
cell metabolism and prevent autophagy and apoptosis (Lin
et al., 2011). Here we identify four peptide sequences within
these domains that bind PDGF-BB. In doing so, we discovered
a 14-mer peptide that bound PDGF-BB and promoted cell
survival, whether bound to a surface or presented to cells in
fluid phase. Attributes of these FN-GFB peptides have
important implications in tissue engineering.
RESULTS
First FNIII has two PDGF–binding sites
To define peptide sequences that bind PDGF-BB and support
cell survival in FN-GFB domains (Lin et al., 2011), we first
focused on the first type III repeat of FN (FNIII1)(Figure 1b)
because the bioactive peptide, anastellin (FN630-704), resides
within this domain and has been reported to promote FN
fibrillogenesis (Ohashi and Erickson, 2005) and antitumor
activity (Yi and Ruoslahti, 2001). To study whether anastellin
interacted with PDGF-BB (125I-labeled), anastellin was
expressed with a cysteine (Cys) tag at the C terminus for
sulfhydryl coupling to SulfoLink beads. From equilibrium-
binding assays, anastellin–PDGF-BB interaction gave a KD of
90 nM (Figure 1c). This finding was confirmed by kinetic-
binding assays using plasmon surface resonance (Figure 1d;
KD¼22.9 nM).
To determine which peptide sequence(s) within anastellin
bind(s) PDGF-BB, FN630-667 and FN668-704, representing
the first and second halves of anastellin, were synthesized with
Cys at their C termini. ELISA equilibrium-binding assays
demonstrated that PDGF-BB bound FN630-667 with a KD of
210 nM and FN668-704 with a KD of 80 nM. Plasmon surface
resonance confirmed binding of PDGF-BB to FN630-667 and
FN668-704 (Supplementary Figure S1 online). These results
demonstrated that FNIII1 contains two PDGF-BB-binding
sequences. Although it was known that FNIII1 domain bound
PDGF-BB (Lin et al., 2011), the finding of two growth factor–
binding sequences in this domain was a surprise.
Four peptides from three FN-GFB domains bound PDGF-BB
To determine whether similar peptide sequences existed in
the two halves of anastellin, the two halves were analyzed
by the PRATT software (Swiss Institute of Bioinformatics,
Lausanne, Switzerland), a program that interactively generates
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Figure 1. Peptide from first fibronectin type III repeat (FNIII1) binds platelet-derived growth factor-BB (PDGF-BB). (a) Schematic of human FN. FN type I repeats
are shown as thin rectangles, FN type II repeats as ovals, and FN type III repeats as thick rectangles. PDGF-BB and cell-binding sites are indicated (arrows).
(b) Sequence of FNIII1 (FN609-718). Sequences of P1 (FN634-658) and P2 (FN680-704) are underlined. (c) Equilibrium binding of PDGF-BB with anastellin
(FN630-704). (d) Kinetic binding of PDGF-BB with FN630-704. Increasing concentrations (6.25–200 nM) of FN630-704 were injected across the biosensor
chip coupled with PDGF-BB (first arrow), followed 120 seconds later by a continuing flow of buffer (second arrow). Chip without PDGF-BB was used as a
reference. KD was calculated by averaging the koff divided by kon. Sensorgrams are representative of three different experiments. c.p.m., counts per minute;
RU, relative units.
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conserved patterns from a series of unaligned proteins. Two
sequences—FN634-658 (QPSHISKYILRWRPKNSVGRWKEAT)
from the first half of anastellin and FN680-704 (QLISHQQYG
HQEVTRFDFTTTSTST) from the second half of anastellin—
were found, and designated P1 and P2 (Supplementary
Figure S2a online), respectively. To study whether these two
25-amino-acid peptides interacted with PDGF-BB, pep-
tides were synthesized with a Cys at the C terminus for
coupling to SulfoLink beads. ELISA equilibrium-binding assay
using 125I-PDGF-BB showed P1 and P2 binding with KDs of
250 and 110 nM, respectively (Supplementary Figure S2b and
c). Interestingly, the P1 binding data fit a sigmoid binding curve
(Supplementary Figure S2f online) better than the classic
hyperbola curve shown in Supplementary Figure S2b online.
The sigmoid curve had a Hills coefficient of 1.38, indicating
modest cooperative binding between two sites. As PDGF-BB is
an antiparallel homodimer, these data suggested that P1 binds
both ends in a cooperative manner.
Next, we searched for other growth factor–binding
sequences in FN, as well as all other proteins in the human
proteome database using ScanProsite (Swiss Institute of Bio-
informatics), a program that scans a sequence against
PROSITE or a pattern against the UniProt Knowledgebase
(Swiss-Prot and TrEMBL). Peptide sequences with similar
patterns were found within FNIII13 and IIICS, two domains
that we previously reported had PDGF-BB-binding activity
(Lin et al., 2011). These two FN peptides were designated P3
(FN1853-1877) and P4 (FN2043-2076), respectively (Supple-
mentary Figure S2a online). Equilibrium-binding assays
with Cys-tagged P3 and P4 demonstrated that 125I-PDGF-BB
bound P3 and P4 with a KD of 87 and 56 nM, respectively
(Supplementary Figure S2d and e online). Thus, four PDGF-
BB-binding peptides with similar sequence patterns were
found within the three FN-GFB domains. Furthermore, a fifth
similar sequence with growth factor–binding activity was
found in the provisional matrix protein, vitronectin, but none
other in the entire human proteome database.
FN-GFB peptides coupled to CBD/14 supports survival and
decreases autophagy and apoptosis of FN-null cells in the
presence of PDGF-BB
Previously, we showed that FN cell–binding domain (FNIII8–11)
did not support FN-null fibroblast survival in the presence of
1 nM PDGF-BB without the presence of a FN-GFB domain,
i.e., FNIII1, FNIII13, or IIICS (Lin et al., 2011). FNIII8-11 (cell-
binding domain) fused to the FN 14th type III repeat (CBD/14)
has been reported to prevent cell spreading, thereby inducing
anoikis and apoptosis (Dai et al., 2005). However, CBD/14 in
the presence either of FNIII1, FNIII13, or IIICS promoted
optimal FN-null cell survival and response to PDGF-BB; the
results are similar to those shown previously (Lin et al., 2011).
This finding led us to investigate whether FN-GFB peptides
when coupled to CBD/14 supported FN-null cell survival.
To address this question, cell survival assays were carried
out in serum-free medium on wells precoated with FN or
with glutathione S-transferase (GST)-CBD/14 fusion product±
tethered FN-GFB peptides. As shown previously, GST
markedly improves protein adsorption to tissue culture plate
surfaces (Lin et al., 2011). Results showed that FN-null cells
could not survive on CBD/14 even in the presence of PDGF-
BB (Figure 2a). When cultured in serum-free DMEM plus 1 nM
PDGF-BB, cells survived on surfaces precoated with CBD/14
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Figure 2. Fibronectin-growth factor binding (FN-GFB) peptide coupled to CBD/14 (cell-binding domain fused to the FN 14th type III repeat) supported
FN-null fibroblast responsiveness to platelet-derived growth factor-BB (PDGF-BB). Cells were plated in 96-well (a, b and d) or 6-well (c) plates precoated
with 0.125mM FN or glutathione S-transferase (GST)-tagged CBD/14±tethered peptide and cultured in serum-free DMEM±PDGF-BB at 37 1C for 3 days.
(a and b) Viable cells in five 10 fields were counted in three wells at 3 days (mean±SD, n¼ 15). (c) Light chain 3-II (LC3-II) was detected by a size
shift on western blot using a polyclonal antibody specific for LC3. (d) Apoptosis was determined by TUNEL at 3 days. Percent apoptosis was calculated from
(positive cells per total cells) 100. Fifty cells were counted in three replicate plates. Data points indicate mean±SD. Each panel represents at least three
experiments. *Po0.05 compared with CBD/14. P1s, scrambled P1.
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coupled to any one of the four FN-GFB peptides (Figure 2a),
but did not survive on CBD/14 coupled to scrambled peptides
(Figure 2b). Cell attachment was similar under all conditions
(Supplementary Figure S3a online). Not surprisingly, FN-null
cell metabolism was robust on FN, mediocre on CBD/14 even
in the presence of PDGF-BB, but almost equivalent to FN
when FN-GFB peptides were coupled to CBD/14 and cultured
with PDGF-BB (Supplementary Figure S3b online).
FN-null cells cultured on FN-CBD/14 increased autophagy
at 24 hours compared with those growing on FN even in the
presence of PDGF-BB, as judged by quantification of total
cellular light chain 3 (LC3), an inducible autophagosome
component (Supplementary Figure S3c online), and western
blot analysis for LC3-II, a cleaved LC3 product that is bound to
autophagosomes (Figure 2c) (Klionsky et al., 2012). When
CBD/14 was coupled to FN-GFB peptides, the accumulations
of LC3 or LC3-II in FN-null cells were significantly decreased
(Supplementary Figure S3b and Figure 2c online, respectively).
Thus, PDGF-BB could decrease autophagy in FN-null cells
when plated on CBD/14 coupled to FN-GFB peptides, but not
in cells on CBD/14 alone. This led us to investigate whether
FN-GFB peptides also promoted the ability of PDGF-BB to
limit apoptosis in FN-null cells cultured on CBD/14. FN-null
cells showed little apoptosis up to 24 hours in all conditions
(data not shown). FN-null cells cultured on FN showed low
levels of apoptosis at 3 days, even in the absence of PDGF-BB
(B7%), whereas PDGF-BB failed to prevent apoptosis in
FN-null cells plated on CBD/14 (30% apoptosis at 3 days
without PDGF-BB; 23% apoptosis with PDGF-BB) (Figure 2d).
When FN-null cells were plated on CBD/14 coupled with a
FN-GFB peptide, apoptosis was significantly decreased in the
presence of PDGF-BB (Figure 2d).
Only P1 inhibited PDGF-BB binding to FN and FN-GFB domains
Next, we studied whether soluble FN-GFB peptides inhibited
PDGF-BB binding to FN or FN-GFB domains (FNIII1, FNIII13,
or IIICS). Binding assays of 125I-PDGF-BB to FN or FN-GFB
domains were carried out in the presence of FN-GFB peptides
at various concentrations. At 4mM, P1 inhibited over 75%
binding of PDGF-BB to FN, and at 40mM, the binding was
nearly completely inhibited (Figure 3a). Scrambled P1 (P1s),
with the same amino-acid composition and molar concentra-
tions as P1, failed to inhibit PDGF-BB binding to FN
(Figure 3a). Authentic P1 also inhibited PDGF-BB binding to
FNIII1, which contains P1 sequences (Figure 3b), as well as
PDGF-BB binding to the other FN-GFB domains. Specifically,
P1 inhibited PDGF-BB binding to FNIII12–14 and IIICs in a
concentration-dependent manner (Figure 3c and d, respec-
tively). At 40mM, P1 inhibited nearly all the binding of PDGF
to these domains. In contrast, P1s showed no inhibition of
PDGF-BB binding to FN or any FN-GFB domain (Figure 3b–d).
Surprisingly, P2, P3, and P4 also failed to inhibit PDGF-BB
binding to FN (Figure 3a) or any FN-GFB domain, even their
parent domain (Figure 3b–d).
The ability of P1 to inhibit PDGF-BB binding to FN and to
the three FN-GFB domains was not surprising, as FN-GFB
peptides within these domains shared a similar sequence
pattern. Furthermore, P1, when added in solution, significantly
enhanced the survival of FN-null cells on CBD/14 in the
presence of PDGF-BB (Figure 3e). Similar results were found
for the survival of adult human dermal fibroblasts (AHDFs)
growing in serum-deprived medium for 6 days (Figure 3f).
Consistent with the lack of effect on FN-null cell survival, P2,
P3, and P4 showed little effect on AHDF survival even in the
presence of PDGF-BB (Figure 3f). Taken together, the inhibi-
tion experiments and the experiments with individual FN-GFB
peptides in solution demonstrated that P1 had special growth
factor–binding properties, such as cooperative binding shown
in Supplementary Figure S2f online, which potentiated its
ability to promote cell survival.
P12 is the shortest FN-derived peptide to enhance FN-null cell
survival
To determine the minimal amino-acid sequence that
enhanced cell survival, we investigated whether P11, a
20-residue peptide from the first third of anastellin that
terminates after RWRPK, a vasoactive peptide described by
the Hocking group (Hocking et al., 2008), had PDGF-BB-
binding and FN-null cell survival activity (Supplementary
Table S1 online). P11 and P5, which overlap with P1 and
P11, bound PDGF-BB and promoted PDGF-BB survival
signals (Supplementary Table S1 online). Next, a series of
peptides were obtained by progressively trimming P5, starting
from either N or C termini (Supplementary Table S2 online),
and were tested for bioactivity. Only P12, a peptide with one
residue deletion from the N terminus of P5, supported FN-null
cell survival in the presence of PDGF-BB (Supplementary
Figure S4a online) and inhibited PDGF-BB binding to FN
(Supplementary Figure S4b online). Real-time binding studies
showed that P12 interacted with PDGF-BB with a KD of
200 nM, and tissue culture investigations demonstrated that
P12 could collaborate with PDGF-BB to enhance AHDF
survival in serum-free medium (Supplementary Figure S5
online). These results demonstrated that P12, a 14-mer
peptide, was the smallest peptide with P1 activity.
P12 enhanced AHDF survival under stress conditions
The unique ability of soluble P12 to enhance FN-null cell
survival led us to investigate whether P12 could also enhance
tissue cell survival under stress conditions. AHDFs were
challenged with ROS stress or endoplasmic reticulum stress.
AHDFs in the presence of serum were challenged with
hypoxanthine/xanthine oxidase (HO/XO) or hydrogen per-
oxide (H2O2). The HO/XO system generates constant low
levels of ROS, whereas H2O2 is a bolus ROS insult. AHDFs
were sensitive to both HO/XO (Supplementary Figure S6a
online) and H2O2 (Supplementary Figure S6b online). In the
HO/XO system, cell death was inhibited when P12 was
introduced 20 hours earlier or at the same time with oxidative
stress. With H2O2, P12 only showed protective effect on
AHDF survival when AHDFs were preincubated with P12
before H2O2 challenge. P12 in the presence of PDGF-BB or
serum also promoted cell survival when endoplasmic reti-
culum stress was induced by tunicamycin (Tun), as judged by
the XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetra-
zolium-5-carboxanilide) assay (Figure 4).
F Lin et al.
PDGF-BB Enhancers Promote Cell Survival
1122 Journal of Investigative Dermatology (2014), Volume 134
As endoplasmic reticulum stress is coupled to Jun N-term-
inal kinase (JNK) activation (Urano et al., 2000), which can
lead to cell death by apoptosis (Urano et al., 2000; Lin et al.,
personal communication), P12 effects on (JNKs) activation
were investigated. After AHDFs were exposed to Tun in the
presence of PDGF-BB±P12 or P12s, phosphorylated JNK
(p-JNK) was determined by immunoblotting (Figure 4a and
b). In the presence of 1 nM PDGF-BB, but in the absence of
P12, Tun significantly increased p-JNK by 4 hours. However, in
the presence of both PDGF-BB and P12, p-JNK induction was
markedly inhibited, whereas P12s showed a minimal effect.
P12 limited burn-injury progression in a rat hot comb model
The effect of P12 on burn-injury progression was assessed
in a rat hot comb burn model, as described in the
Materials and Methods section and in our previous publi-
cation (Singer et al., 2011). Each hot comb contained four
brass prongs that left three 5-mm non-burned inter-
spaces. Burn-injury progression across the interspaces was
assessed both visually and histologically. When P12 was
infused 1 hour after burns, injury progression into the
interspaces between burns was inhibited in a dose–response
manner (Figure 5).
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Figure 3. Soluble P1 inhibited platelet-derived growth factor-BB (PDGF-BB) binding to fibronectin (FN) and FN-growth factor binding (FN-GFB) domains,
and supported FN-null cell and adult human dermal fibroblast (AHDF) survival. (a–d) 125I-radiolabeled PDGF-BB was incubated with FN or glutathione
S-transferase (GST)-tagged FN-GFB domain-coated wells. After washing, radioactivity of bound PDGF-BB was determined using a g-counter. (e) Fluid-phase
P1 supported FN-null cell survival on CBD/14 (cell-binding domain fused to the FN 14th type III repeat). FN-null fibroblasts were plated at 4,000 cells
per well (96-well-plates) precoated with 0.125mM GST-tagged CBD/14 in serum-free DMEM±1nM PDGF-BB±10mM peptide at 37 1C for 3 days. Viable cells in
five 10 fields were counted in three wells (mean±SD, n¼ 15). (f) Fluid-phase P1 supported AHDF survival under serum-starvation conditions. AHDFs were
plated at 1,000 cells per well (96-well plates) in serum-free DMEM and cultured overnight, and then changed to DMEM±1nM PDGF-BB±10mM peptide was
added, cells were cultured for 6 days, and viable cells were counted. Data shown are mean±SE (n¼ 4).
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DISCUSSION
From our results, P12, a peptide from the first type III repeat of
FN, appeared to act as a cofactor of PDGF-BB, enhancing its
ability to promote survival of cells under stress. In addition, we
found a similar peptide in vitronectin (Lin and Clark, unpub-
lished data). Although it was previously established by us (Lin
et al., 2011) and others (Wijelath et al., 2006; Martino and
Hubbell, 2010) that FN can directly bind growth factors, and
thereby enhance their activity, this is the first report that
localized growth factor–binding and –enhancing activity to
specific peptides within FN domains. We propose naming this
new class of bioactive peptides that act as cofactors of growth
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Figure 5. P12 intravenous infusion 1 and 24 hours after burn inhibited injury progression. (a and b) Burn at 7 days after injury without treatment.
(c and d) Burn at 7 days after injury that had been treated with 10 mg kg 1 P12. (e) Viable interspaces 2, 5, and 7 days after injury in rats treated or not
treated with P12. (f) Viable interspaces 7 days after injury determined by histologic analysis. 0¼ Infusion with lactated Ringer’s buffer. Variance of interspace
viability among rats within a specific treatment arm was no more than variance among interspaces on a given rat; therefore, interspace data for all five rats per
treatment arm were pooled; n¼30 interspaces (6 interspaces per rat) in five rats per treatment arm. Bar¼ 10 mm.
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factors, particularly promoting their cell survival activity,
epiviosamines from the Greek word epivios, the adjective of
the verb epiviono, which means ‘‘to survive in the face of
adversity.’’ The prefix epivios has been combined with
‘‘amine,’’ used to indicate a substance made from peptides.
Historically, vita, the Latin word for life, was combined with
amine to make the word vitamin for the same reason.
However, when it was discovered that vitamins were not
peptides, the ‘‘e,’’ from amine, was dropped.
Interestingly, the FN peptide P12, which had the most
robust PDGF-BB-binding activity and which was active in
solution, was found within the amino terminus of anastellin, a
76-mer peptide that promotes FN fibrillogenesis (Ohashi and
Erickson, 2005), inhibits endothelial cell growth, and has
antiangiogenesis activity (Yi and Ruoslahti, 2001). Preliminary
investigations of P12 bioactivity on human dermal
microvascular endothelial cells demonstrated that P12 did
not inhibit human dermal microvascular endothelial cell
metabolism when the cells were cultured with 10 ng ml 1
vascular endothelial growth factor in endothelial cell growth
medium, whereas anastellin inhibited human dermal
microvascular endothelial cells (McTigue M, Tonnesen MG
and Clark RAF, unpublished observations). In contrast,
fibroblast survival was not inhibited by anastellin in solution
and was enhanced when anastellin was adsorbed on the
culture dish. Furthermore, the carboxy terminus of P12 con-
tains RWRPK, the carboxy terminus of vasoactive peptides
previously described by the Hocking group (Hocking et al.,
2008). Although P12 has vasodilation activity on the
microvascular bed of a hamster cheek pouch (Frame MD,
Lin F and Clark RAF, personal communication), RWRPK does
not collaborate with PDGF-BB to promote survival of FN-null
cells. In fact, the Hocking group demonstrated that the
RWRPK by itself inhibits cell growth (Hocking et al., 2008).
Thus, anastellin, P12, and RWRPK are nested peptides within
the FN first type III repeat that have distinctly different
biological activities.
The Hubbel group previously demonstrated that FNIII12–14
bound a large number of growth factors (Martino and Hubbell,
2010) including PDGF-BB, as we confirmed (Lin et al., 2011).
Furthermore, we have confirmed that FNIII12–14, as well as
FNIII1 and IIICS, bind multiple, but not all, growth factors.
Often, only a few members of a growth factor family bind FN.
From the differential binding of FN-GFB domains to growth
factors, we have delineated peptide sequences within these
growth factors to which P1, P2, P3, and P4 bind (Lin F and
Clark RAF, personal communication). In fact, preliminary
computer modeling done by Wallqist and Rollins at Ft
Detrick, Frederick, MD, demonstrated a probable P12
docking site at the interface of PDGF-BB and the PDGF-BB
receptor (PDGFR-b) that contains the putative PDGF-BB-
binding partner peptide for P12. As there are two sites for
P12 binding to the PDGF-BB antiparallel dimer, the
cooperative binding pattern observed for P1 interaction with
PDGF-BB is not surprising.
More recently, the Hubbell group demonstrated that multi-
ple recombinant domains of FN, including the central cell-
binding domain (FNIII9–10) and the promiscuous FNIII12–14
growth factor–binding domain, greatly enhanced the regen-
erative effects of growth factors in a diabetic mouse model and
a critical-size rat bone defect (Martino et al., 2011). In
addition, the Hocking group recently demonstrated that FN
recombinant fusion products consisting of the latter half of
FNIII1 fused to FNIII8-10 enhanced wound healing in a diabetic
mouse model (Roy et al., 2013). Taken together, these two
groups have used FN domains that contain three out of
the four peptides that we have determined are the growth
factor–binding sites in FN. The ability of P12 to limit burn-
injury progression adds further evidence that FN growth
factor–binding sites have utility in tissue survival and healing.
JNKs have a critical role in cell apoptosis initiated by both
extrinsic and intrinsic pathways (Verma and Datta, 2012). To
date, three JNKs, namely JNK1, JNK2, JNK3, encoded by three
distinct genes have been identified (Johnson and Nakamura,
2007). In response to specific stimuli such as heat shock,
reperfusion injury, ER, and oxidative stress, JNK proteins are
activated by phosphorylation at its Thr or Tyr residues of a TXY
motif. JNKs in turn activate apoptotic signaling either through
the upregulation of pro-apoptotic genes via the transactivation
of specific transcription factors including c-Jun or by directly
modulating the activities of mitochondrial pro- and anti-
apoptotic proteins through phosphorylation. Here we
demonstrate that P12 promoted the ability PDGF-BB to
suppress JNK activation. Therefore, the downregulation of
the JNK pro-apoptotic pathway may be responsible in part for
the decreased apoptosis observed of cells under stress that
were treated with P12. The ability of P12 to limit burn-injury
progression in a rat hot comb model is consistent with this
hypothesis.
With elucidation of more epiviosamines such as P12, we
will increase our understanding of how extracellular matrix
proteins can enhance growth factor signaling in such a way to
sustain cell survival in the setting of tissue stress (Macri et al.,
2007). In addition, the findings described here will increase
the number of small peptide bioactives that can be added to
tissue-engineered products to induce tissue survival and
regeneration (Clark, 2013).
MATERIALS AND METHODS
Materials
Recombinant PDGF-BB was obtained from Biosource (Camarillo, CA)
and 125I-PDGF-BB from Amersham Biosciences (Piscataway, NJ).
Human plasma FN was purchased from Chemicon (Temecula, CA)
and found to be 99% pure and intact by SDS-PAGE. SulfoLink
coupling beads was acquired from Pierce (Rockford, IL). Fatty acid–
free BSA was purchased from ICN Biomedicals (Aurora, OH). Ni-NTA
agarose beads were acquired from Qiagen (Valencia, CA). Isopropyl
b-D-1-thiogalactopyranosideb and lysogeny broth were purchased
from Fisher Scientific (Fair Lawn, NJ) and fetal bovine serum from
Hyclone (Logan, UT). Culture plates were from BD Bioscience
(Billerica, MA). The Cell proliferation kit II (XTT) was from Roche
Diagnostics (Indianapolis, IN). LC3 polyclonal antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA) and Novus Biologicals
(Littleton, CO). BIAcore 2000, CM5 sensor chips, N-hydroxysuccini-
mide, N-ethyl-N0-(3-diethylaminopropyl)carbodiimide hydrochloride,
and 1 M ethanolamine (pH 8.5) were purchased from BIAcore
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(Piscataway, NJ). Peptides were synthesized by Bio-synthesis (Lewis-
ville, TX) and PEGDVS was acquired from NEKTAR Transforming
Therapeutics (Huntsville, AL).
Expression and purification of FN functional domains
Methods for cloning, expression, and purification of recombinant
human FN domains and fusion products of FN domains with GST
were published previously (Wang et al., 2005). GST tag on the N
terminus of the recombinant proteins facilitated FN domain
adsorption onto tissue culture plastic for cell function studies. We
also previously described cloning, expression, and purification of Cys-
tagged FN domains (Ghosh et al., 2006). Cys-tagged FN domains
allowed linkage to SulfoLink agarose beads with minimal impact on
protein conformation.
Equilibrium binding of PDGF-BB with FN or peptides
Cys-tagged FN peptides were conjugated to agarose beads via –SH
groups, using the manufacturer’s protocol (SulfoLink Coupling Gel).
To block nonspecific binding, agarose beads, conjugated with or
without FN or FN peptides, were incubated with 2% BSA at room
temperature for 2 hours. For equilibrium binding, 20ml of conjugated
agarose beads were incubated with varying concentrations of
125I-labeled PDGF-BB in binding buffer (DMEMþ 1% BSA) at room
temperature for 2 hours with rotation. After washing, the radioactivity
bound to the agarose beads was quantified using a g-counter.
The binding constant of PDGF-BB with FN or FN domains was
determined using Prism 4 nonlinear regression software (GraphPad,
San Diego, CA).
Kinetic-binding assay of PDGF-BB with peptides
Using the BIAcore 2000 plasmon resonance system, kinetic binding
constants were determined by passing varying concentrations of
analytes dissolved in 20 mM HEPES, 150 mM NaCl, 3.4 mM EDTA,
and 0.05% Tween-20, pH 7.4, over chip surfaces coupled with either
PDGF-BB or purported FN-GFB partner, which were immobilized
on the Sensor Chips as described previously (Lin et al., 2011). All
kinetic experiments were carried out at 20 1C at a flow rate of
30ml minute 1. For mass transport experiments, each analyte was
injected at a fixed concentration and run at flow rates ranging from
5 to 75ml minute 1. All analytes were injected over a PDGF-coupled
surface, as well as over a control surface for 120 s, followed by 300 s
of dissociation in running buffer. Regeneration of the sensor chip for
subsequent injections was accomplished by one pulse of 0.05% SDS
(30 s). Sensorgrams were prepared and globally fitted using nonlinear
least-squares analysis and numerical integration of differential rate
equations following the BIAcore manual and using kinetic models
available in BIAevaluation software (Biacore Life Science,
Piscataway, NJ).
Cell culture
Mouse FN-null fibroblasts generated as described previously
(Saoncella et al., 1999) and AHDF (passages 5–13; Clonetics, San
Diego, CA) were maintained in DMEM supplemented with
100 U ml 1 penicillin, 100mg ml 1 streptomycin, and 10% fetal
bovine serum at 37 1C and 5% CO2/95% air in a humidified
atmosphere. For cell function assays, fibroblasts were grown to
approximately 80% confluence, harvested, and transferred to tissue
culture plates in assay-appropriate numbers.
Mouse FN-null cell survival assays on FN domains
Cell survival experiments were performed in 96-well plates that
had been coated with 0.125mM of FN, CBD/14, or CBD/14
coupled with various peptides, as described previously (Lin et al.,
2011). After blocking with 2% BSA for 2 hours to exclude
further protein binding, plates were washed with phosphate-
buffered saline. For each well, 4,000 FN-null cells were plated and
incubated at 37 1C for 4 hours. Next, 25ml of 5% BSA in DMEM
was added to each well±PDGF-BB or FN peptides, and wells
were incubated for the durations indicated. Cell survival was
assayed by counting cells and by XTT according to the
manufacturer’s protocol.
TUNEL assay
Apoptotic cells were identified by nick end labeling using the In Situ
Cell Death Detection Kit and TMR red, as described previously (Lin
et al., 2011).
Analysis of the autophagosome protein LC3
ELISA for total LC3 and western blots of LC3-I and LC3-II were
performed as described previously (Lin et al., 2011).
Rat hot comb burn model
Animal experiments were approved by the IACUC at Stony Brook
University (Stony Brook, NY). Sprague–Dawley rats with a weight
around 350 g were used. After removing hair, two burns were created
on the back of each animal using a brass comb with four rectangular
prongs preheated in boiling water and applied for 30 seconds,
resulting in four rectangular 10 20 mm2 full-thickness burns sepa-
rated by three 5 20 mm2 unburned interspaces (zone of ischemia).
Forty comb burns with 120 unburned interspaces were created and
distributed among control and three doses of P12 (1, 3, and
10 mg kg 1 administered in 1 ml of Lactated Ringer’s solution). An
observer blinded to the treatment determined necrotic interspaces at
2, 5, and 7 days. Full-thickness biopsies from interspaces 7 days after
injury were processed, stained with hematoxylin and eosin, and
evaluated for evidence of necrosis by a board-certified dermato-
pathologist (SAM) blinded to the protocol.
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